A Phase 1, Randomized, Placebo Controlled, Double-Blind, Single Dose Escalation Study of NoNO-42 in Healthy Adults
Latest Information Update: 21 May 2024
At a glance
- Drugs NoNO 42 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
- Sponsors NoNO
Most Recent Events
- 13 May 2024 Status changed from recruiting to completed.
- 08 Sep 2023 Planned End Date changed from 1 May 2023 to 10 Oct 2023.
- 08 Sep 2023 Planned primary completion date changed from 1 May 2023 to 10 Oct 2023.